Testicular Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand

Global testicular cancer therapeutics market is growing with the increasing prevalence of testicular cancer. The market is expected to witness moderate growth, since there are already more than 15 drugs that exist in the market for the treatment of testicular cancer. Increasing prevalence of cancer and rising demand for the medications with better efficacy and less side effects can be attributed as an opportunity for oncology. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing increased funding, designations and grants for speeding up the drug development process. 

Testicular cancer is the tumor that develops in the testicles. Testicles are the glands found in men that produce testosterone hormone and sperms. The cause of testicular cancer is attributable to enormous growth of testicular cells due to some abnormalities, resulting in the formation of tumor in testicles, causing testicular cancer. Cryptorchidism, inguinal hernia, congenital abnormalities, abnormal testicular development and family history can increase the risk of testicular cancer. Mumps orchitis are also one of risk factors which is a very rare complication of mumps, which involves the inflammation of testicles. Pain, swelling, discomfort, sensation of heaviness and sudden fluid accumulation in scrotum are the main symptoms of testicular cancer.

Request to Get the Sample Pages at: 

Growing prevalence of testicular cancer and combination therapies for the treatment are the major driving forces for the testicular cancer therapeutics market. Also with no drug in Phase III, there is a need for growth in pipeline for better treatment options, providing increased opportunities to the players in the market. Some of the marketed drugs for the treatment of testicular cancer include Blenoxane (Bleomycin), Cisplatin, Cosmegen (Dactinomycin), Cyfos (Ifosfamide), Etopophos (Etoposide Phosphate) and Velban (Vinblastine Sulfate). Some of the drug combination available in the market are BEP, JEB, PEB, VIP and VeIP.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=testicular-cancer-therapeutics-market

The treatment is more effective if the chemotherapy regimen involves two or more drugs rather than using any single drug. Therefore, chemotherapy is expected to have major share in the global testicular cancer therapeutics market.

Some of the key players operating in the global testicular cancer therapeutics market are Ovation Pharmaceuticals, Inc., ZIOPHARM Oncology Inc., Bristol-Myers Squibb Company, Hospira Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG and Teva Parenteral Medicines, Inc.

Read More

Esophageal Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2024

Global esophageal cancer therapeutics market is expected to witness significant growth with an increasing awareness regarding cancer treatment and technological advancements. Also, high demand for safe and effective medications and rising prevalence of cancer are driving the growth of the global market. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process.

Esophageal cancer involves formation of malignant cells in the tissues of the esophagus. Esophagus is a muscular tube that enable food and liquids to move from the throat to the stomach. The main types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Adenocarcinoma forms in cells that produce and release mucus and other fluids. Squamous cell carcinoma forms in flat cells lining the esophagus. Esophageal squamous cell carcinoma includes heavy alcohol consumption and smoking as major risk factors, with gastroesophageal reflux disease and Barrett esophagus further contributing as the risk factors of esophageal adenocarcinoma. Esophageal cancer has no early signs or symptoms; therefore, an advanced stage diagnosis is difficult.

Request to Get the Sample Pages at: 

Some of the major drivers for the global esophageal cancer therapeutics market include combination therapies, treatment advancements, increasing number of regulatory approvals for esophageal cancer and a rise in the number of cancer treatment centers. Moreover, the launch of new drug therapies for esophageal cancer is expected to contribute as a key market driver in the near future. Also with a dense pipeline, many new drug candidates are expected to enter the global esophageal cancer therapeutics market. Safety concerns and efficacy of the treatment are the major factors that can hinder the market growth over the forecast period. Other factors hampering the market growth include low availability of drugs commercially and high cost of therapy for the treatment of esophageal cancer.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=esophageal-cancer-therapeutics-market

Certain chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine are well established as a conventional method. Immunotherapy, combination therapy, monoclonal antibodies and steroids have also been showing good results for the treatment of esophageal cancer.

Some of the key players operating in the global esophageal cancer therapeutics market include Genentech, Inc., Sanofi-Aventis, Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., Merck & Co., Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, Gilead Sciences, and Bristol-Myers Squibb, among others.

Read More

Infectious Disease Treatment Market Outlook - Top Companies, Trends and Future Prospects Details for Business Development

Infectious diseases are medical conditions or disorders caused by microorganisms such as bacteria, fungi, viruses and other parasites. Several organisms are present in and on human bodies. Some organisms are normally harmless and even helpful. However, under certain circumstances, some organisms cause diseases. Infectious diseases spread from one person to another. Moreover, some are transmitted by bites from insects and animals. Infectious diseases also occur by consumption of contaminated food and water.

Signs and symptoms of infectious diseases depend on the type of organism and infection. Some of the most common symptoms of infectious diseases include fatigue and fever. Mild complaints of infectious diseases treated from rest and home remedies, while some life-threatening infections require hospitalization. Infectious diseases, such chickenpox and measles are prevented by vaccination. Frequent and thorough hand-washing also protect human body from infectious diseases.

Download Report Sample at:

North America dominates the global infectious disease treatment market followed by Europe. The U.S., followed by Canada, is the largest market for infectious disease treatment in the North American region. Key driving factor for infectious disease treatment market in the region is increasing research activities on various types of diseases. Germany, France and the U.K. are some of the largest markets for infectious diseases in Europe. However, Asia-Pacific represents the fastest growing region in the global infectious disease treatment market. This is due to minimal wages and availability of skilled professionals in the region. These factors attract drug manufacturing companies to invest in the Asian countries. In addition, in developing countries, such as China and India, government has launched several programs and initiatives to increase awareness about infectious diseases. China, Japan and India are largest infectious disease treatment markets in the region.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=infectious-disease-treatment

Increasing prevalence of the infectious diseases is key driving factor for the global infectious disease treatment market. Increasing awareness and extensive R&D drugs pipelines are also enhancing the growth of global infectious disease market. Moreover, introduction of novel drugs, such as direct-acting antivirals, boosts the growth of global infectious disease treatment market.

However, patent expiry of various major drugs and presence of generic drugs are key restraint of the global infectious disease treatment market. Stringent regulations and legislations and side-effects of anti-infective drugs also hinder the growth of global infectious disease treatment market. Rapid product launches and increasing mergers and acquisitions between drug manufactures are emerging trends of the global infectious disease treatment market.

Some of the major competitors in the global infectious disease treatment market are F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Johnson & Johnson, Pfizer, Gilead Sciences,  Bristol-Myers Squibb Company, AstraZeneca, Bayer AG, Novartis, Sanofi, AbbVie and Auritec Pharmaceuticals.

Read More

Cytomegalovirus Retinitis Market Comprehensive Review of its Applications Growth Opportunities and Future Prospects

One of the major trends noticed in the cytomegalovirus retinitis market is usage of off-label drugs for the treatment of cytomegalovirus retinitis. Innovation of products focusing on better efficacy, growing demographics and growing economies in the developing countries, such as China and India, are some of the opportunities for global cytomegalovirus retinitis market.

Cytomegalovirus retinitis is eye disease caused due to retina inflammation of eye. The causative agent of the disease is cytomegalovirus, a herpes virus that affects the photosensitive cells of retina. After affecting the retina, the disease spreads from one eye to another eye, which can lead to blindness, if left untreated. Photophobia, blurred vision, seeing floaters and blind spots are the symptoms of cytomegalovirus retinitis. Cytomegalovirus retinitis usually affects people with weak immune system, including HIV affected patients. Various forms of cytomegalovirus retinitis medication are solutions, capsules, tablets and implants.

Request to Get the Sample Pages at: 

  

Some of the major factors restraining the growth of the global cytomegalovirus retinitis market are lack of awareness among people for different types of eye diseases, rising healthcare cost in developing countries and lack of healthcare insurance. Majority of the population do not have proper access to primary healthcare services because of poverty and absence of health insurance, which is also hindering the growth of cytomegalovirus retinitis market. The other major challenge for the global cytomegalovirus retinitis market is lack of approved treatment guidelines by the World Health Organization (WHO).

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cytomegalovirus-retinitis-market

North America has the largest market for cytomegalovirus retinitis due to improved medical facilities and increasing occurrence of cytomegalovirus retinitis cases in the region. Asia-Pacific is growing with the highest rate among global cytomegalovirus retinitis market. In Asia-Pacific, China and India are the two fastest growing cytomegalovirus retinitis markets, attributed to raising government initiatives and support and large population in these countries.

Some of the major competitors of global cytomegalovirus retinitis market are, Shire Plc, F. Hoffmann-La Roche AG, Hospira Inc., Chimerix Inc., Gilead Sciences Inc., pSivida, Auritec Pharmaceuticals Inc., Sanofi S.A., and Isis Pharmaceuticals Inc.

Read More

Chronic Lymphocytic Leukemia (CLL) Therapeutics Market Analysis by Stages, Drug Class, Company Profile, Phase of Development, and Discovery Stage Insights

The global chronic lymphocytic leukemia therapeutics market is expected to create more opportunities in oncology due to promising pipeline and positive clinical data of drug candidates. The existing drugs for the treatment of chronic lymphocytic leukemia is the be most effective treatment. The American Cancer Society, and other regulatory bodies are supporting the chronic lymphocytic leukemia therapeutics market by providing funding and grants. The market is being driven by different factors such as rising awareness for the cancer treatments, high demand for safe and effective medications, technologies advancements, and increasing prevalence of cancer.

Chronic lymphocytic leukemia is a type of gradually developing leukemia that affects the development of B lymphocytes (also known as B cells). On the other hand, B cells are specialized white blood cells, which produce immunoglobulins (also called antibodies) under normal conditions, and help to protect the human body against infections and diseases. In patients with chronic lymphocytic leukemia, lymphocytes undergo a malignant change and become leukemic cells.

Request to Get the Sample Pages at: 

Ono Pharmaceutical and Bristol-Myers Squibb are in the process of developing Opdivo for the treatment of chronic lymphocytic leukemia. Genentech is developing Atezolizumab, also known as MPDL 3280A, for chronic lymphocytic leukemia therapeutics, which is in Phase II stage. Atezolizumab is a monoclonal antibody targeting programmed cell death-1 ligand 1 (PD-L1). PD-L1 plays an important role in suppressing the immune system triggered by the cancer. PD-L1 acts by reducing the proliferation of antigen-specific CD8+ T-cells and controlling the accumulation of foreign antigen-specific T-cells.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=chronic-lymphocytic-leukemia-therapeutics-market

The chronic lymphocytic leukemia is more prevalent in North America, making the region to be the largest revenue contributor, globally. The U.S. contributed the largest revenue to the North American market in year 2016, and it is expected to remain the largest market across the globe, during the forecast period.

Some of the key players operating in the chronic lymphocytic leukemia therapeutics market are GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Celgene Corporation, Biogen Inc., AbbVie, Inc., Teva Pharmaceuticals Limited, Gilead Sciences, Inc., Novartis AG, and Johnson & Johnson.

Read More

Restless Legs Syndrome Market Performance and Market Share, Sales Revenue and Major Manufacturers Performance, Gross Margin Analysis

Restless legs syndrome or RLS is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.

The exact reason behind the restless legs syndrome is not known precisely, however, it is believed the disease is caused due to genetic factors or due to iron deficiency in the brain or due to the disorders in dopaminergic balance.

The exact treatment of this disease is not present till now. However the available drug in the market helps in the indicative treatment of the disease. Some of the drug in the restless legs syndrome market such as sulfonamide by safinamide by Newron Pharmaceuticals reduces the symptoms by novel action such as potent, reversible and selective inhibition of MAO-B, without disturbing the MAO-A and dopamine uptake. This enhances the glutamate release and dopaminergic function of the patients; it also reduces the dopamine degradation. One other drug: SER-214 manufacture by Serina is used widely in the restless legs syndrome treatment; it uses a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology this drug can be combined with the polymer and transported to the patients.

Request to Get the Sample Pages at: 

Based on the different product type the global restless legs syndrome market can be broadly classified as Mirapex/Sifrol/Mirapexin, Neupro/Leganto, Requip, and HORIZANT/Regnite. On the basis various disease type the global restless legs syndrome market can be broadly bifurcated as etiology and pathogenesis, iron deficiency, genetic factors, neurological disturbances and others. Based on the mode of the therapy the global restless legs syndrome market can be broadly segmented into two broad categories: pharmacological therapy and non-pharmacological therapy.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=restless-legs-syndrome-market

Some of the major players operating in the global restless legs syndrome market include, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, Manhattan Pharmaceuticals, Boehringer Ingelheim GmbH, UCB SA.

Read More

Nuclear Medicine (Radiopharmaceuticals) Market by Overview, Growth Opportunities, Manufacturing Cost Structure Analysis, Outlook and Industry Insights Forecast to 2024

The global nuclear medicine/radiopharmaceuticalsmarket is growing significantly due to increasing prevalence of cancer and cardiovascular diseases, and advances in nuclear medicine imaging procedures. High demand of nuclear medicines in emerging economies and potential radiopharmaceuticals in the pipeline create ample opportunities for the nuclear medicine/radiopharmaceuticals market to grow at a considerable rate in the coming years.

The advances in neurological applications and development of new products by the companies are supporting to address the demand for cost effectiveness of radiopharmaceuticals. Nuclear medicine imaging procedures are non-invasive and can be used for the treatment of several diseases, such as cancers, cardiovascular diseases, and neurological disorders.

Request to Get the Sample Pages at: 

The nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and region. On the basis of type, the nuclear medicine/radiopharmaceuticals market can be segmented as diagnostics and therapeutics. The diagnostics segment leads the nuclear medicine/radiopharmaceuticals market. The diagnostics segment can be further categorized into single-photon emission computed tomography (SPECT) and positron emission tomography (PET). SPECT segment will be leading the nuclear medicine/radiopharmaceutical diagnostics market in the coming years due to its wider availability and less cost. The therapeutics segment can be further categorized into beta emitters, alpha emitters, and brachytherapy isotopes. The beta emitters will be the leading segment in the global nuclear medicine/radiopharmaceutical therapeutics market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=nuclear-medicine-market

Geographically, North America will be leading the global nuclear medicine/radiopharmaceuticals market in the coming years due to increasing prevalence of cancer, ready availability of radiopharmaceuticals, popularity of nuclear medicine among physicians, and technological advancements.

Asia-Pacific is the fastest growing region in the global nuclear medicine/radiopharmaceuticals market. The major reasons for the fastest growth in the region are increasing healthcare expenditure, and rising awareness of radiopharmaceuticals among healthcare providers. Moreover, Japan will be leading the nuclear medicine/radiopharmaceuticals market in Asia-Pacific region in the coming years.

Some of the major players operating in the global nuclear medicine/radiopharmaceuticals market are GE Healthcare, Bayer Healthcare, Cardinal Health Inc., Eczacibasi-Monrol Nuclear Products, Bracco Imaging S.p.A, Nordion Inc., Lantheus Medical Imaging Inc., Advanced Accelerator Applications S.A, Mallinckrodt plc, and IBA Molecular Imaging.

Read More

Diabetic Retinopathy Market Comprehensive Review of its Applications Growth Opportunities and Future Prospects

Diabetic retinopathy refers to an eye disorder that damages or harms the blood vessels of the retina. Diabetic retinopathy can cause permanent blindness. Chronic diabetes is a major root of diabetic retinopathy.

The treatment procedure of diabetic retinopathy depends on the various stages of diabetic retinopathy. It is one of the most dominant reasons of blindness in U.S adults. According to WHO, about 347 million patients were suffering from diabetes globally as of 2012, and among those 347 million patients 11% of those were effected from diabetic retinopathy.  In the U.S. alone, there were 4.1 million people were impacted from the diabetic retinopathy as of 2012. 

 Request to Get the Sample Pages at: 

North America was the largest market for diabetic retinopathy in 2014. The market dominance of North America is attributed to the high obesity rate and large diabetic patients in this region. Moreover the supportive government initiative is also one of the important drivers of the market in this region.

Europe was the second largest market of diabetic retinopathy in 2014, the large population of baby boomers in Europe is one of the dominate growth factors for the diabetic retinopathy market in this region. Asia Pacific is expected to show the highest growth over the next five years. The lucrative growth of the diabetic retinopathy market in Asia Pacific is attributed to the presence of a large number of diabetic patients in India and China. Moreover, growing health awareness coupled with rising expenditure on healthcare services is also fueling the diabetic retinopathy market in this region. Country wise the U.S. is the largest market of diabetic retinopathy in North America. Germany, Spain, Italy, U.K and France are some of the major diabetic retinopathy market in Europe. China, Japan, India are some of the major market diabetic retinopathy in Asia Pacific region. Under Rest of the World section Brazil is the largest market of diabetic retinopathy.   

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=diabetic-retinopathy-market

  

Some of the major players operating in the global diabetic retinopathy market include, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, Valeant Pharmaceuticals International Inc., Abbott Laboratories Ltd., Alimera Sciences Inc., Ampio Pharmaceuticals Inc., Bausch & Lomb Inc., Boehringer Ingelheim GmbH, iCo Therapeutics Inc., Lupin Ltd., Parexel International Corp., Quark Pharmaceuticals Inc., Thrombogenics NV, and Vitreoretinal Technologies Inc. 

Read More

Diabetic Nephropathy Market Opportunities by Types, Demand, Top Manufactures and Application in Grooming Regions

The increase in research and development funds for drug discovery followed by growing awareness of kidney-related disorders, and diabetes are the major factors driving the expansion of the global diabetic nephropathy market.

Diabetes is a disease defined by high blood sugar level, caused by inappropriate functioning of the pancreas (the organ which secretes insulin in the body). Nephropathy means kidney impairment or damage. Diabetic nephropathy is the impairment or damage to the kidneys caused by diabetes.

It is a disease which affects the kidney glomerulus and one of the most major issues for diabetic patients. Not only the person with diabetes has to undergo kidney impairment, but also the acute cases of diabetic nephropathy could lead to kidney miscarriage. The disease affects the kidneys in a way that makes it futile. Progressive growth in proteinuria and failure in renal function, hypertension, and high risk of cardiovascular disease are the major side effects of chronic diabetic nephropathy. Blood pressure (BP) control is necessary in minimizing the progression of diabetic nephropathy. Irrespective of the agent used, lower blood pressure in type II diabetics could slow down the start and progression of diabetic nephropathy.

Request to Get the Sample Pages at:

On the basis of mode of treatment, the global diabetic nephropathy market is segmented into disease modifying therapies and others. Disease modifying therapies is further categorized into diuretics, angiotensin-converting enzyme inhibitors, antioxidant inflammation modulator, angiotensin receptor blockers, renin inhibitors, calcium channel blockers, connective tissue growth factor inhibitors, monocyte chemoattractant proteins inhibitor, G protein-coupled receptors and endothelin (a receptor antagonist).

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=diabetic-nephropathy-market

Various government programs are spreading cognizance about diabetes and related renal complications in North America. For example, the National Kidney Disease Education Program (NKDEP) is one of the most important programs organized by the U.S. government, for growing awareness about the various kidney diseases.

Lack of complete therapeutic management for diabetic nephropathy, longer approval time for drugs as well as, harsh regulatory requirements are hampering the market growth of global diabetes nephropathy market.

Some of the major competitors in the global diabetic nephropathy market are Novartis AG, Merck & Co., Inc., Pfizer Inc., Abbott Laboratories, Sanofi, Eli Lilly and Company, Reata Pharmaceuticals, Inc., Bayer AG, AbbVie Inc., and Mitsubishi Tanabe Pharma Corporation.

Read More

Biopharmaceuticals Market Size, Share, Development, Growth and Demand

View more on edocr

Read More

Asthma Market to Witness the Highest Growth Globally in Coming Years

Asthma is a respiratory condition, where the airways become inflamed and narrow, which can cause a serious and incurable condition if left untreated. Breathlessness, wheezing and coughing are some of the symptoms of asthma and it can be controlled by avoiding triggers and with the help of drug therapy. Environmental triggers may vary from consumer to consumer but it can include exercise, smoke, cold air and other allergens such as pollen, dust mites, and infections. The wheezing in asthma begins when the chemicals present in the lungs overreact to the dust mites, cold air and exercise.

According to Centers for Disease Control and Prevention (CDC), asthma is an ordinary chronic airway disorder which is characterized by swelling of air passages that convey air from mouth and nose to lungs. Asthma is caused generally due to allergies leading to inflammation of lungs. GlaxoSmithKline Pharmaceuticals Limited and Novartis AG are developing once-a-day combination products that are longer acting than currently available drugs and more suitable for patients due to its advantage of being taken only once a day.

Request to Get the Sample Pages at: 

Based on drug class, the global asthma market can be categorized bronchodilators, combination therapies, mast cell stabilizers, leukotriene antagonists and immunosuppressants. On the basis of route of administration, the global market is segmented into oral, inhaled and other route of administrations.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=asthma-market

Daily exposure to hazardous working environment, influx of pollutants in the air, increase in population susceptible to indoor air pollutants, increase in disposable income, increasing population of smokers, improved healthcare facility, and growing aging population are some of other the major factors that are driving the growth of asthma market. Factors that are restraining the growth of asthma market are high cost of asthma treatment, patent expiry of many best-seller brands and long treatment continuation. Additionally, lack of diagnostic tools for reliable asthma diagnosis in young children is also limiting the growth of global asthma market.

Some of the major competitors of global asthma market are, Ono Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd. Merck & Co., Inc., Astrazeneca plc, Sunovion Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim GmbH, Koninklijke Philips N.V., and F. Hoffmann La-Roche Ltd.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)           

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Breast Cancer Market Comprehensive Analysis of Market Trends, Technological Advancements, Company Profile and Growth Opportunities

Cancer is a disease characterized by uncontrolled growth of cell. There are about 100 different types of cancer and each is classified by the type of cell where it occurs and affects. Breast cancer is mostly prevalent in women, however, breast cancer in men is rare. It is frequently diagnosed in aged women and one of the leading causes of death among them. Some of the most common types of breast cancer are ductal carcinoma in situ (DCIS), lobular carcinoma and invasive ductal carcinoma.

DCIS, also known as intraductal carcinoma, begins in the lining of the milk ducts. Milk ducts are thin tubes carrying milk from lobules of the breast to the nipple. Lobule carcinoma originates in the lobules or milk glands of the breast. Invasive ductal carcinoma is the most common type of breast cancer. It starts in a milk duct of the breast, ruptures through the wall of the duct and grows into the fatty tissue of the breast. It spreads to other parts of body through bloodstream.

Request to Get the Sample Pages at:

North America accounts the largest global breast cancer market followed by Europe. The U.S., followed by Canada, is the largest market for breast cancer in North America. Key driving factor for this market is increasing prevalence of breast cancer in the region. Germany, France and the U.K. are some of the largest markets for breast cancer in Europe region. However, Asia-Pacific represents the fastest growing region in the global breast cancer market. This is due to improving healthcare infrastructure and increasing awareness among people about breast cancer. In developing countries, such as China and India, government has launched several programs and initiatives which increase awareness about the disease. It has led to significant rise in demand of breast cancer diagnostics and therapeutics for disease management. In addition, less stringent wages and availability of skilled labor attracts manufacturing companies to invest in developing countries. 

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=-breast-cancer-market

Increasing prevalence of the disease is a key driving factor for the global breast cancer market. Increasing awareness among people about the disease and rising number of geriatric women around the world are also supporting the growth of global breast cancer market. In addition, increased research in the field of oncology and development of biomarker has also fueled the growth of global breast cancer market. Increasing demand of advanced therapeutic drugs and extensive drug pipeline holds immense potential to the growth of the global breast cancer market.

Some of the major competitors in the market are Astrazeneca PLC, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Novartis AG, Sanofi-Aventis. Pfizer, Inc., Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc and Teva Pharmaceutical Industries Ltd.

Read More

Bile Duct Cancer Therapeutics Market Has Been Classified on the Basis of Disease Indication, Treatment Type and Geography

Bile duct cancer is also known as cholangiocarcinoma. It involves the presence of mutated epithelial cells originated in the bile ducts. However, the cause of bile duct cancer (cholangiocarcinoma) is not certain. There are some factors that can increase the chances of developing bile duct cancer (cholangiocarcinoma).

The most common symptoms of bile duct cancer (cholangiocarcinoma) include abdominal pain, abnormal liver function, generalized itching, weight loss, discoloration of stool and urine, etc. The risk factor of bile duct cancer (cholangiocarcinoma) include liver fluke infections, cholangitis and exposure to thorium dioxide. According to American Society of Clinical Oncology (ASCO), less than 3,000 people are affected with the disease, every year, in the U.S. Also, according to Cancer Research UK, about 1,600 people are affected by the disease, every year, in the U.K. The existing treatment options for bile duct cancer (cholangiocarcinoma) are mainly dominated by generics and off-label drugs, and provide only symptomatic relief. 

Request to Get the Sample Pages at:

The global bile duct cancer therapeutics market has been classified on the basis of disease indication, treatment type and geography. Based on disease indication, the global bile duct cancer therapeutics market has been segmented into perihilar (hilar) bile duct cancers, distal bile duct cancers, and intrahepatic bile duct cancers. Based on treatment type, the global bile duct cancer therapeutics market has been segmented into chemotherapy, chemoradiation and stent insertion. Based on region, the global market has been segmented into Latin America, North America, Asia-Pacific, Middle East & Africa, and Europe.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=bile-duct-cancer-therapeutics-market

Geographically, North America has been the largest market for bile duct cancer therapeutics. The growth of the regional market can be attributed to adequate reimbursement policies, greater awareness toward health care and advanced healthcare facilities. The Asia-Pacific and European markets for bile duct cancer therapeutics are projected to record strong CAGRs, over the forecast period.

Some of the key players in the global bile duct cancer therapeutics market include, Bayer, AG, Delcath Systems Inc., Senhwa Biosciences, Inc., PCI Biotech, Inc., ASLAN Pharmaceuticals, Inc., RedHill Biopharma Ltd. and Halozyme Therapeutics, Inc. among several others.

Read More

Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, Growth and Demand Forecast to 2023

The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants and designations. Thus, these regulatory bodies are amplifying the drug development process. 

Benign prostatic hyperplasia is also known as benign prostatic obstruction or benign prostatic hypertrophy, is a disease state in men, caused by prostate gland enlargement. Prostate develops in dual phase in entire life – the first phase occurs in initial phase of puberty, followed by the second phase that usually begins at the age of twenty-four and remains for most of a person’s life. Benign prostatic hyperplasia is a common problem in men aged above 50 years, and it occurs in the second phase of growth of prostate. However, the disease can also arise in men aged below 40 years, with the probabilities of its occurrence increasing with age.

Request to Get the Sample Pages at:

Aging population is the major factor on which the benign prostatic hyperplasia therapeutics market is mostly dependent. Asia-Pacific and European markets for benign prostatic hyperplasia therapeutics are likely to observe significant growth rates, during the forecast period, due to increase in aging population in these regions. The Latin American and North American markets for benign prostatic hyperplasia therapeutics are also projected to observe strong growth rates, during the forecast period.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=benign-prostatic-hyperplasia-therapeutics-market

Some of the key players operating in the global benign prostatic hyperplasia therapeutics market include Sandoz, Inc., Sanofi Aventis, Labopharm, Inc., Pfizer, Inc., and Teva Pharmaceuticals, Inc.

Read More

Acute Myeloid Leukemia (AML) Therapeutics Market by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The global acute myeloid leukemia therapeutics market is expected to witness notable growth, in the coming year due to increase in the new innovative and targeted drug delivery system. Various factors such as rising awareness regarding cancer treatments, increasing demand for safe and successful medications, rising incidence of cancer and technological advancements have been driving the growth of the global acute myeloid leukemia therapeutics market. Apart from this, various regulatory bodies are supporting the growth of the global market with funding, designations and grants, thereby accelerating the drug development process.

According to National Cancer Institute, a part of the U.S. National Institutes of Health, acute myeloid leukemia is a type of cancer that affects the blood and bone marrow. Acute myeloid leukemia is characterized by overproduction of immature white blood cells, myeloblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. They can also spill out into the blood stream and circulate around the body. Due to their immaturity, these cells are unable to prevent or fight infections.

Download Report Sample at:

The pipeline of acute myeloid leukemia contains Durvalumab, a Phase II drug candidate of MedImmune. It is a fully human monoclonal antibody, which helps to overcome the immunosuppressive effects of B7-H1 on T-cells. Takeda Pharmaceutical Company Limited is developing a Phase II drug candidate, Alisertib, for the treatment of acute myeloid leukemia. It is an orally active, small-molecule inhibitor of the aurora A kinase. The aurora family of protein kinases is involved in the regulation of cell growth and proliferation, particularly in chromosome segregation and cytokinesis.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=acute-myeloid-leukemia-therapeutics-market

The acute myeloid leukemia therapeutics market was the largest market in the U.S. region of North America in year 2016, and it is expected to remain the largest during the forecast period due to large number of research and development activities.

Some of the key players operating in the acute myeloid leukemia therapeutics market include Celgene Corporation, Eisai Co. Ltd., Bristol-Myers Squibb, Novartis AG, F. Hoffman La Roche AG, Genmab A/S, GlaxoSmithKline plc, and Takeda Pharmaceutical Company Limited.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:

P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)           

International: +1-347-960-6455

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More